[免疫检查点抑制剂在癌基因驱动的晚期非小细胞肺癌中的应用进展]
[Application Progress of Immune Checkpoint Inhibitors in Oncogene-driven Advanced Non-small Cell Lung Cancer].
作者信息
Zhang Tongmei, Li Baolan
机构信息
Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):188-195. doi: 10.3779/j.issn.1009-3419.2021.101.04.
Abstract
With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment options upon exhaustion of targeted therapies are limited. Immune checkpoint inhibitors (ICIs) can bring long-term survival to some patients with advanced NSCLC because of its unique long tailing effect. More and more studies have shown that ICIs can also benefit NSCLC patients with oncogenic drivers. However, the timing of ICIs intervention, the therapeutic regimen and the predictive biomarkers are actually debated, underscoring the need to explore the potential interest of ICIs in these populations. .
摘要
随着精准医学的发展，靶向治疗极大地改善了具有致癌驱动因素的晚期非小细胞肺癌（NSCLC）患者的生存率和预后。然而，无论哪种靶向治疗都不可避免地会产生治疗耐药性，靶向治疗用尽后的治疗选择有限。免疫检查点抑制剂（ICIs）由于其独特的长尾效应，可以为一些晚期NSCLC患者带来长期生存。越来越多的研究表明，ICIs对具有致癌驱动因素的NSCLC患者也有益处。然而，ICIs的干预时机、治疗方案和预测生物标志物实际上仍存在争议，这突出了探索ICIs在这些人群中的潜在价值的必要性。
相似文献
1
[Application Progress of Immune Checkpoint Inhibitors
in Oncogene-driven Advanced Non-small Cell Lung Cancer].[免疫检查点抑制剂在癌基因驱动的晚期非小细胞肺癌中的应用进展]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):188-195. doi: 10.3779/j.issn.1009-3419.2021.101.04.
2
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].[晚期非小细胞肺癌且PD-L1高表达患者对免疫检查点抑制剂单药治疗或联合化疗反应的评估]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02.
3
Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm.PD-1/PD-L1 轴免疫检查点抑制剂在非小细胞肺癌中的应用：新型治疗模式中的前景、争议和不确定性。
Scand J Clin Lab Invest. 2020 Sep;80(5):360-369. doi: 10.1080/00365513.2020.1742369. Epub 2020 Apr 2.
4
[Chinese Experts Consensus on Immune Checkpoint Inhibitors
for Non-small Cell Lung Cancer (2020 Version)].《中国非小细胞肺癌免疫检查点抑制剂临床应用专家共识（2020年版）》
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):217-235. doi: 10.3779/j.issn.1009-3419.2021.101.13. Epub 2021 Apr 26.
5
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?何时考虑在驱动基因非小细胞肺癌中使用免疫检查点抑制剂？
Curr Treat Options Oncol. 2019 Jun 6;20(7):60. doi: 10.1007/s11864-019-0652-3.
6
Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的非小细胞肺癌成人的体能状态和临终关怀。
Cancer. 2020 May 15;126(10):2288-2295. doi: 10.1002/cncr.32782. Epub 2020 Mar 6.
7
Immunotherapy in advanced non-small-cell lung cancer with mutations.携带 突变的晚期非小细胞肺癌的免疫治疗。
Immunotherapy. 2020 Nov;12(16):1195-1207. doi: 10.2217/imt-2020-0148. Epub 2020 Sep 27.
8
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).免疫检查点抑制剂在 KRAS 突变型非小细胞肺癌（NSCLC）中的疗效。
J Thorac Oncol. 2019 Jun;14(6):1095-1101. doi: 10.1016/j.jtho.2019.01.011. Epub 2019 Feb 6.
9
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
10
[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer
with Rare Mutation].免疫检查点抑制剂治疗非小细胞肺癌罕见突变的疗效
Zhongguo Fei Ai Za Zhi. 2021 Jan 20;24(1):19-24. doi: 10.3779/j.issn.1009-3419.2020.102.41.
引用本文的文献
1
Matrine alkaloids modulating DNA damage repair in chemoresistant non-small cell lung cancer cells.苦参碱生物碱调节化疗耐药非小细胞肺癌细胞中的 DNA 损伤修复。
BMC Cancer. 2024 Oct 16;24(1):1283. doi: 10.1186/s12885-024-12991-3.
本文引用的文献
1
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.一项在 EGFR 突变阳性局部晚期/转移性非小细胞肺癌的 EGFR TKI 初治患者中进行的吉非替尼联合度伐利尤单抗的 1 期研究。
Br J Cancer. 2021 Jan;124(2):383-390. doi: 10.1038/s41416-020-01099-7. Epub 2020 Oct 5.
2
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.度伐利尤单抗用于三线或更后线晚期非小细胞肺癌的最终总生存期和安全性更新：II期ATLANTIC研究
Lung Cancer. 2020 Sep;147:137-142. doi: 10.1016/j.lungcan.2020.06.032. Epub 2020 Jun 30.
3
The National Lung Matrix Trial of personalized therapy in lung cancer.国家肺癌矩阵试验：肺癌个体化治疗。
Nature. 2020 Jul;583(7818):807-812. doi: 10.1038/s41586-020-2481-8. Epub 2020 Jul 15.
4
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.表皮生长因子受体突变型非小细胞肺癌患者接受免疫检查点抑制剂治疗获益的特征。
Cancer Immunol Immunother. 2021 Jan;70(1):101-106. doi: 10.1007/s00262-020-02662-0. Epub 2020 Jul 10.
5
Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma.ALK重排的肺腺癌对抗PD-1治疗的完全且持久反应
Lung Cancer. 2020 Aug;146:366-369. doi: 10.1016/j.lungcan.2020.05.008. Epub 2020 May 27.
6
Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients.抗程序性死亡-1联合抗血管生成疗法在非小细胞肺癌患者中的真实世界治疗疗效
Medicine (Baltimore). 2020 Jun 12;99(24):e20545. doi: 10.1097/MD.0000000000020545.
7
Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition.帕博利珠单抗在Keynote-001研究中实现5年生存突破：免疫检查点抑制为晚期非小细胞肺癌带来新视野。
Ann Transl Med. 2020 Apr;8(8):555. doi: 10.21037/atm.2020.01.87.
8
Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients.免疫疗法的疗效与非小细胞肺癌患者特定肿瘤突变基因特征之间的关系。
Thorac Cancer. 2020 Jun;11(6):1647-1654. doi: 10.1111/1759-7714.13447. Epub 2020 Apr 27.
9
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.塔顿：奥希替尼联合塞来替尼、索凡替尼或度伐鲁单抗治疗 EGFR 突变型肺癌的多臂 Ib 期试验。
Ann Oncol. 2020 Apr;31(4):507-516. doi: 10.1016/j.annonc.2020.01.013. Epub 2020 Jan 24.
10
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.抗PD-1免疫疗法在伴有BRAF、HER2或MET突变或RET易位的晚期非小细胞肺癌患者中的疗效和安全性：GFPC 01-2018
J Thorac Oncol. 2020 Apr;15(4):628-636. doi: 10.1016/j.jtho.2019.12.129. Epub 2020 Jan 13.
Zotero 插件